Arca
Skip to content

Cold agglutinin disease

Drug research and approvals for cold agglutinin disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 4 studies of cold agglutinin disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 2 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 4
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 2
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 4 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
May 17, 2022A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of pegcetacoplan in patients with cold agglutinin…PEGCETACOPLAN (APL-2)Swedish Orphan BiovitrumClosed
Sep 15, 2020An open label, long term, safety and tolerability study of patients with cold agglutinin disease previously treated with bivv020BIVV020SANOFI-AVENTIS CANADA INCPending
Feb 11, 2020A multicenter, phase 1b, open label, nonrandomized, single dose study evaluating the safety, tolerability and activity of bivv020 in adults with cold…BIVV020SANOFI-AVENTIS CANADA INCOngoing
Dec 15, 2017A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of bivv009 in patients with primary cold agglutinin disease…BIVV009SanofiOngoing
Dec 15, 2017A pivotal, open-label, multicenter study to assess the efficacy and safety of bivv009 in patients with primary cold agglutinin disease who have a recent…BIVV009SanofiClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Jan 25, 2023Enjaymotreatment of hemolysis in adults with cold agglutinin disease (CAD)Recordati Rare Diseases Inc.Approved
Feb 4, 2022EnjaymoTo decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD)Recordati Rare Diseases Inc.Approved

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Nov 15, 2022Enjaymosutimlimab · orphanRecordati Rare DiseasesEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.